What Series A Health-Tech Investors Actually Want to See on the Provider Traction Slide

A caveat first. I have not been on the GP side of a venture firm. What I have done is spent the last several years working with VPs of Commercial at Series A health-tech companies as they prepared for Series B fundraises. I have read decks. I have sat through diligence calls. I have seen which slides survived scrutiny and which got picked apart.

The patterns below come from that vantage. It is partial. A founder reading this should treat it as a working hypothesis, not a definitive guide.

What the slide actually has to do

The provider traction slide is the one that most often determines whether a Series B conversation continues. Product slides, market slides, team slides, all negotiable. Provider traction is the slide where investors are looking for evidence that the company can repeatedly land contracted relationships with health systems, specialty practices, payers, or whichever provider buyer the company is targeting.

If that slide is weak, the rest of the deck does not save the round.

What I have noticed is that VPs of Commercial often build this slide late. They treat it as a reporting exercise on what already happened. The companies that raise cleanly tend to build it much earlier, sometimes within the first ninety days of the VP joining. They treat it as the operating north star, not a deliverable.

That timing difference seems to matter more than people give it credit for.

What investors are actually evaluating

The most common mistake I see is loading the slide with logos. Logos are necessary but they are not what gets evaluated. What investors are looking for, based on the questions I have heard them ask in diligence calls, is closer to:

Does the contract land last? Are there expansion or renewal signals, or is there churn we should be worried about?

Is the customer acquisition motion repeatable? Are these contracts coming through founder relationships, inbound, or a structured outbound motion that can scale with capital?

What is the time from first meeting to signed contract? Is that number stable or are early customers moving faster than later ones?

What does pipeline look like beyond the contracts that already closed?

A logo wall does not answer any of these questions. It just shows that the company has talked to important institutions, which is table stakes by the time you are raising Series B.

The annotated structure

Rather than prescribe a structure, here is one that has survived diligence at companies I have worked with, with notes on why each section gets the attention it does.

Contracted customers section. Logos, contract dates, contract values where allowed, expansion or renewal status. What does not belong here: letters of intent, unpaid pilots, design partner contracts that never converted to commercial terms. Investors will ask, and labeling them honestly upfront builds more trust than burying them and getting caught.

Pipeline by stage. Number of opportunities at qualified, late-stage, and verbal commit stages, with the conversion rate assumptions you are using to forecast. What does not belong here: aggregate pipeline value figures with no stage breakdown. That number is meaningless to a sophisticated investor and they will know it is meaningless.

Acquisition source mix. Percentage of contracted revenue from inbound, outbound by channel, and founder-sourced relationships. This is the section that tends to separate companies that raise from companies that struggle. If 80% of contracted revenue traces back to founder relationships, the investor is looking at a company that has not yet proven its commercial motion can run without the founder. That is a legitimate concern at Series B. A VP of Commercial whose first ninety days have produced contracts through outbound, inbound, or contract field reps can shift that mix in a way that materially changes the diligence narrative.

Time-to-close trend. Median days from first qualified meeting to signed contract, broken down by quarter. A single average hides whether the motion is getting faster or slower, and the investor wants to see the trajectory, not the snapshot.

Net retention or expansion. Dollar-weighted retention if you have enough customers to compute it honestly, qualitative expansion narrative if you do not. Manufactured retention numbers based on three customers do more damage than admitting the data set is too small.

The acquisition source mix section is where I would spend the most time if I were preparing this deck. It is also the section most VPs of Commercial spend the least time on.

Where source mix becomes the whole story

I want to walk through a comparison that came up in two Series B raises within six months of each other, because it is illustrative.

Both companies targeted specialty practices. Both raised Series A within six months of each other. Both were preparing for Series B eighteen months post-Series A.

Company A had nineteen contracted customers at the time of the Series B deck. Company B had eleven. On logo count, Company A looked stronger.

In diligence, the investor asked both companies to break down acquisition source.

Company A's nineteen contracts: fifteen sourced through the founder's existing network, two through inbound, two through a part-time SDR.

Company B's eleven contracts: three founder-sourced, six through three contract field reps placed nine months earlier, two through inbound.

Company B also had thirty-one qualified opportunities in pipeline, all from the contract reps. Company A had eight qualified opportunities, all from the founder's network.

Company B closed the Series B at a higher valuation despite fewer logos. The investor flagged Company A's founder dependency as the reason for declining. Company A eventually raised a smaller round at a flat valuation.

I have observed versions of this pattern several times. The total customer count matters less than the source mix and the trajectory. An investor doing diligence on a Series B is buying the next two years of growth. They are evaluating whether the commercial motion can produce that growth without the founder being the constraint.

What this means operationally

If you are a VP of Commercial who joined a Series A health-tech in the last sixty days, the practical question is what you should be building toward in the next four to six quarters to make this slide work.

The rough trajectory I have observed at companies that raised cleanly:

In quarters 1 and 2, stand up a structured outbound motion in two or three target territories or verticals. This is the moment to decide whether to do that with W2 reps, contract reps, or a hybrid. Each path has its own runway implications, and the decision compounds for eighteen months. (I have written about that decision separately in the first commercial hire piece, so I will not repeat it here.)

In quarters 3 and 4, generate enough closed contracts through the new motion to shift the source mix away from founder dependency. The exact number varies, but I would target at least 40% of new contracted ARR coming from non-founder-sourced acquisition by the end of quarter four.

From quarter 5 onward, build pipeline depth. The Series B deck needs late-stage opportunities, not just closed deals. Investors want to see what the next four quarters of revenue could look like, and that requires twenty to forty late-stage opportunities by the time the deck goes out.

This is aggressive, and not every Series A health-tech can hit this trajectory. Companies with longer enterprise sales cycles (nine to eighteen months) will need more runway between hire and contract. Companies selling to specialty practices and ambulatory care can usually move faster.

The trap

The biggest operational trap I see is treating the provider traction slide as a quarterly reporting exercise rather than an operating plan.

The slide has to be assembled from a CRM that captures source attribution, stage history, and deal velocity. If those fields are not being maintained from quarter one, the slide that gets built eighteen months later is a reconstruction. Investors can usually tell.

A practical thing to do in week three of a new VP role: audit whether the CRM is capturing acquisition source, first-touch date, and stage transition timestamps. If it is not, fix it before adding any new pipeline activity. The cost of fixing it later, when you are trying to assemble a deck under fundraise pressure, is much higher than fixing it early.

A note on contract structure

Investors care about contract structure as much as logo count. A company with eight contracts at $200K average annual contract value with two-year terms is structurally stronger than a company with twelve contracts at $80K average annual contract value with one-year terms. Even though the second company looks more impressive on a logo wall.

Contract field reps in health-tech often help with this because they tend to be more disciplined about pushing for multi-year terms during initial negotiation. A founder running sales personally is sometimes willing to trade contract length for a faster close. A senior contract rep is typically not. That difference shows up in the Series B deck eighteen months later as net retention.

It is one of the less-obvious reasons the source mix matters. The reps you hire shape the contract terms you sign, which shape the retention math two years later.

One last note. The provider traction slide is also where I have seen Series B fall apart over things that have nothing to do with the slide itself. A weak product slide can be defended in the Q&A. A weak market slide can be reframed. A weak provider traction slide is the one that makes investors quietly stop returning calls, because they have already done the math on whether your motion is repeatable, and they have already concluded it is not. Build it like you are building the case for the next two years of growth, because that is what investors are buying.